| Literature DB >> 25518036 |
Dennis de Carvalho Ferreira1, Glaucilene Rodrigues da Silva2, Fernanda Sampaio Cavalcante2, Flavia Lima do Carmo3, Leonardo Alexandre Fernandes4, Suelen Moreira2, Mauro Romero Leal Passos5, Ana Paula Vieira Colombo6, Katia Regina Netto dos Santos2.
Abstract
Staphylococcus aureus is an important cause of infections and HIV-infected individuals are frequently susceptible to this pathogen. The aim of this study was to perform a systematic review to identify both the risk factors associated with colonization/infection by methicillin-resistant S. aureus in HIV patients and the methods used for characterization of isolates. An electronic search of articles published between January 2001 and December 2013 was first conducted. Among 116 studies categorized as being at a quality level of A, B or C, only 9 studies were considered to have high methodological quality (level A). The majority of these studies were retrospective (4/9 studies). The risk factors associated with colonization/infection by S. aureus were use of antimicrobials (4/9 studies), previous hospitalization (4/9 studies) and low CD4+ T lymphocyte counts (<200 cells/μl) (3/9 studies). Culture in mannitol salt agar (3/9 studies) and the latex agglutination test (5/9 studies) were the main methods used for bacterial phenotypic identification. Genotypic profiles were accessed by pulsed-field gel electrophoresis (6/9 studies) and USA300 was the most prevalent lineage (5/9 studies). Most isolates were resistant to erythromycin (3/9 studies) and susceptible to vancomycin (4/9 studies). Ultimately, use of antimicrobials and previous hospitalization were the main risk factors for colonization/infection by methicillin-resistant S. aureus in HIV-infected individuals. However, the numbers of evaluated patients, the exclusion and inclusion criteria and the characterization of the S. aureus isolates were not uniform, which made it difficult to establish the characteristics associated with HIV patients who are colonized/infected by S. aureus.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25518036 PMCID: PMC4256048 DOI: 10.6061/clinics/2014(11)11
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Quality evaluation criteria and their scores.*
| Number | Quality Assessment | Yes | No |
| 1 | Representative sample of the target population | 1 | 0 |
| 2 | Definition of the type of study | 1 | 0 |
| 3 | Definition of the inclusion and exclusion criteria applied to the sample | 1 | 0 |
| 4 | Presence of a control group | 1 | 0 |
| 5 | Description of risk factors for colonization and/or infection | 1 | 0 |
| 6 | Phenotypic analysis: Gram staining and catalase and coagulase tests | 1 | 0 |
| 7 | Molecular analysis: SCC | 1 | 0 |
| 8 | Antimicrobial susceptibility analysis: MIC and disk diffusion tests | 1 | 0 |
| 9 | Statistical analysis | 1 | 0 |
| 10 | Discussion of the limitations of the study | 1 | 0 |
Based on criteria established by the PRISM statement. SCCmec: staphylococcal cassette chromosome mec; PFGE: pulsed-field gel electrophoresis; MLST: multilocus sequence typing; MIC: minimum inhibitory concentration.
Figure 1- Outline of the steps for the selection of the studies.
Databases and search results.
| Reference source | Keywords | Total articles | Articles found after applying the inclusion and exclusion criteria | Articles selected based on quality assessment |
| PubMed | HIV | 911 | 23 | 9 |
| SciELO | HIV; | 29 | 12 | 0 |
| LILACS | HIV; | 841 | 17 | 0 |
| Ovid | HIV; | 11 | 5 | 0 |
| Google Scholar | MRSA; HIV; recurrent infections; molecular typing; epidemiology | 1.115 | 10 | 8 |
Scientific Electronic Library Online;
Latin American and Caribbean Health Sciences;
human immunodeficiency virus;
methicillin-resistant Staphylococcus aureus.
Characteristics of the nine selected studies involving HIV patients with colonization and/or infection by Staphylococcus aureus.
| Type of study (country; authors) | Category (score) | Sample size | Clinical source(s) | Factors associated with colonization and/or infection | Phenotypic analysis of isolates | Molecular analysis and virulence/resistance genes investigated | Susceptibility test(s) | Antibiotic resistance rates for |
| Case-control(Italy; Tumbarello et al., 2002) | A (8) | 4,674 HIV-infected patients/129 | Blood | Nosocomial episodes, previous antibiotic therapy and/or bacterial infections | API® test ID 32 STAPH | ND | MIC | CLI 39%; MCL 57%; MET 32%; PEN 73%; QUI 49%; TMP/SXT 70%; VAN 0% |
| Case-control (USA; Hidron et al., 2005) | A (9) | 726 patients/81 HIV-infected patients (14 MRSA)/645 HIV-negative (39 MRSA) | Anterior nares | No antimicrobial use in the past three months before the current admission (only for HIV-infected patients) | SMA; latex agglutination test | PFGE; SCC | Disk diffusion; OAS | CLI 32%; DOX 10%; GEN 23%; MCL 92.5%; OXA 100%; QUI 83%; RIF 20%; TMP/SXT 21%; VAN 0% (data from MRSA isolates, independent of patient classification) |
| Retrospective case-control (Italy; Drapeau et al., 2007) | A (8) | 3,000 patients/28 MRSA | Blood; skin and soft tissue; sputum, bronchoalveolar lavage and pleural fluids | T CD4+ T lymphocyte counts <200 cells/μl; previous hospitalization; an invasive procedure in the previous year | ND | ND | Automated system | ND |
| Retrospective (USA; Burkey et al., 2008) | A (8) | 4,607 patients/216 | Blood | Intravenous drug use; CD4+ T lymphocyte counts <200 cells/μl; end-stage renal disease | ND | ND | OAS | ND |
| Prospective (USA; Shet et al., 2009) | A (8) | 107 patients/41 | Anterior nares | Previous antibiotic therapy | SMA; latex agglutination test | PFGE; SCC | MIC | CLI 43%; MCL 100%; MUP 39%; QUI 95%; TET 24%; TMP/SXT 5% |
| Experimental, randomized controlled trial, prospective (USA; Gordon et al., 2010) | A (8) | 191 | Anterior nares | Relapse of drug or alcohol use within the previous month; previous antibiotic therapy | SMA; latex agglutination test | PFGE | MIC; disk diffusion | CLI 83%; FOX 20%; GEN 9%; MCL 95%; OXA 27%; PEN 99%; QUI 45%; RIF 2%; TET 16%; TMP/SXT 89%; VAN 0% |
| Retrospective et al., 2010) | A (8) | 900 patients/72 MRSA | Skin or soft tissue and normally sterile sites | Previous antibiotic therapy and/or hospitalization; CD4+ T lymphocyte counts <200 cells/μl; drug use; hepatitis B co-infection; OI in the previous year; alternative housing**; incarceration; alcohol abuse | ND | PFGE | ND | TMP/STX 2% |
| Observational (USA; Popovich et al., 2013) | A (8) | 745 patients/374 HIV-infected (74 MRSA)/371 HIV-negative (41 MRSA) | Nares; throat; bilateral axillae; bilateral inguinal regions; peri-rectal area and a chronic wound | Incarceration; male gender | ChromID MRSA; latex agglutination | PFGE | Disk diffusion | ND |
| Cohort (USA; Farley et al., 2013) | A (8) | 498 patients/68 HIV-infected (10 MRSA)/430 HIV-negative (20 MRSA) | Anterior nares; axilla and wound | History of or current abscess; isolation outside the hospital unit; HIV infection (data from all patients, independent of whether they were infected with HIV) | Gram stain; catalase; latex agglutination test | CHROMagar MRSA; automated system | TMP/STX 0%; MUP 7.7% (data from MRSA isolates, independent of patient classification) |
Factors for which odds ratios and 95% confidence intervals were calculated. **Includes patients residing in personal-care homes, nursing homes, long-term care facilities, and correctional facilities as well as those who were homeless. MRSA: methicillin-resistant S. aureus; HIV: human immunodeficiency virus; OI: opportunistic infection; SMA: culture in mannitol salt agar; PFGE: pulsed-field gel electrophoresis; PCR: polymerase chain reaction; PVL: Panton-Valentine leukocidin; TSST1: toxic shock toxin 1; ACME: arginine catabolic mobile element; MIC: minimum inhibitory concentration; CLI: clindamycin; DOX: doxycycline; FOX: cefoxitin; GEN: gentamicin; MCL: macrolides; MET: methicillin; MUP: mupirocin; OXA: oxacillin; PEN: penicillin; QUI: quinolones; RIF: rifampin; TET: tetracycline; TMP/STX: trimethoprim/sulfamethoxazole; VAN: vancomycin; ND: not determined; OAS: oxacillin agar screening.